Paramedic Papers

Home Pain & sedation Low analgesia rates in sickle cell EMS pain

Pain & sedation

Low analgesia rates in sickle cell EMS pain

Prehospital management of pain associated with acute complications of Sickle Cell Disease: a preliminary nationwide cross-sectional study
The American Journal of Emergency Medicine · Added 18 September 2026

US nationwide cross-section of 10,023 9-1-1 ALS encounters for sickle cell disease complications in 2023 — pain scores documented in 73% but only 13.5% received any analgesia (11.7% opioids), and among patients scoring ≥7/10, contact times ≥20 min were associated with roughly five-fold more IV access and ten-fold more analgesia/opioid administration.

Study type
Cross-sectional
Design
Nationwide cross-sectional study of ALS encounters
Participants
10,023 EMS encounters for sickle cell disease complications (5.2% paediatric)
Main finding
Pain scores documented in 73.0%; analgesia given in 13.5% (11.7% opioids); among patients scoring ≥7/10, contact times ≥20 min were associated with roughly five-fold more IV access and ten-fold more analgesia/opioid administration.
Caveat
US dataset; cross-sectional design cannot establish causation and documentation bias likely.
Bottom line
Context only

Why it matters in Australia (Medium relevance). US administrative data and associations, not causation, but vaso-occlusive pain undertreatment maps onto ACTAS pain management (CMG 2) where fentanyl IN and methoxyflurane are in scope.

Learning goal

Strengthen my judgement on providing timely analgesia for severe sickle cell pain when IV access is difficult.

Open in dashboard Read the paper (DOI) PubMed

More

Related papers on Pain & sedation